PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Drugs - Market size and forecast 2018-2023 Vaccines - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DRIVERS AND CHALLENGES Market drivers Market challenges PART 10: TRENDS Increasing efforts by vendors Growing threat of bioterrorism Expedited approvals PART 11: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 12: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bavarian Nordic AS Emergent BioSolutions Inc. Pfizer Inc. SIGA Technologies Inc. PART 13: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 14: EXPLORE TECHNAVIO   Exhibit 01: Vendors: Key offerings Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market characteristics analysis Exhibit 06: Market segments Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: Drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Drugs - Year-over-year growth 2019-2023 (%) Exhibit 23: Vaccines - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Vaccines - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Customer landscape analysis Exhibit 28: Market share by geography 2018-2023 (%) Exhibit 29: Geographic comparison Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Top 3 countries in North America Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 34: Europe - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in Europe Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Asia Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in ROW Exhibit 42: Key leading countries Exhibit 43: Market opportunity Exhibit 44: Decision framework Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendor landscape analysis Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: Bavarian Nordic AS - Vendor overview Exhibit 53: Bavarian Nordic AS - Business segments Exhibit 54: Bavarian Nordic AS - Organizational developments Exhibit 55: Bavarian Nordic AS - Geographic focus Exhibit 56: Bavarian Nordic AS - Key offerings Exhibit 57: Emergent BioSolutions Inc. - Vendor overview Exhibit 58: Emergent BioSolutions Inc. - Business segments Exhibit 59: Emergent BioSolutions Inc. - Organizational developments Exhibit 60: Emergent BioSolutions Inc. - Key offerings Exhibit 61: Pfizer Inc. - Vendor overview Exhibit 62: Pfizer Inc. - Business segments Exhibit 63: Pfizer Inc. - Organizational developments Exhibit 64: Pfizer Inc. - Geographic focus Exhibit 65: Pfizer Inc. - Segment focus Exhibit 66: Pfizer Inc. - Key offerings Exhibit 67: SIGA Technologies Inc. - Vendor overview Exhibit 68: SIGA Technologies Inc. - Business segments Exhibit 69: SIGA Technologies Inc. - Organizational developments Exhibit 70: SIGA Technologies Inc. - Key offerings Exhibit 71: Validation techniques employed for market sizing Exhibit 72: List of abbreviations Exhibit 73: Definition of market positioning of vendors

Bavarian Nordic AS, Emergent BioSolutions Inc., Pfizer Inc., and SIGA Technologies Inc.